Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Debt to Equity (2018 - 2023)

X4 Pharmaceuticals' Debt to Equity history spans 5 years, with the latest figure at $0.01 for Q2 2023.

  • For Q2 2023, Debt to Equity fell 96.05% year-over-year to $0.01; the TTM value through Jun 2023 reached $0.01, down 96.05%, while the annual FY2022 figure was $0.02, 43.88% up from the prior year.
  • Debt to Equity reached $0.01 in Q2 2023 per XFOR's latest filing, up from $0.01 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.29 in Q2 2022 to a low of $0.01 in Q3 2021.
  • Average Debt to Equity over 4 years is $0.11, with a median of $0.04 recorded in 2022.
  • Peak YoY movement for Debt to Equity: surged 2242.8% in 2022, then crashed 96.05% in 2023.
  • A 4-year view of Debt to Equity shows it stood at $0.27 in 2019, then plummeted by 95.5% to $0.01 in 2021, then surged by 43.88% to $0.02 in 2022, then plummeted by 36.3% to $0.01 in 2023.
  • Per Business Quant, the three most recent readings for XFOR's Debt to Equity are $0.01 (Q2 2023), $0.01 (Q1 2023), and $0.02 (Q4 2022).